

1 Title: ADCC-activating antibodies correlate with protection against congenital human cytomegalovirus
2 infection

3 Running title: ADCC antibodies in cCMV infection
4

5 Authors: Eleanor C. Semmes^{1,2}, Itzayana G. Miller^{2,7}, Nicole Rodgers^{2,3}, Caroline T. Phan², Jillian H.
6 Hurst⁴, Kyle M. Walsh^{4,5}, Richard J. Stanton⁶, Justin Pollara^{2,3}, Sallie R. Permar^{2,7*}
7

8 ¹ Medical Scientist Training Program, Department of Molecular Genetics and Microbiology, Duke
9 University, Durham, NC, USA

10 ² Duke Human Vaccine Institute, Duke University, Durham, NC, USA

11 ³ Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA

12 ⁴ Department of Pediatrics, Duke University, Durham, NC, USA

13 ⁵ Department of Neurosurgery, Duke University, Durham, NC, USA

14 ⁶ Division of Infection and Immunology, School of Medicine, Cardiff University, Cardiff, UK

15 ⁷ Department of Pediatrics, Weill Cornell Medicine, New York City, NY, USA
16

17 *Corresponding author: Sallie R. Permar, MD, PhD

18 Email: sallie.permar@med.cornell.edu | Phone: (212) 746-4111

19 Mailing address: 525 East 68th Street, M-622, New York, NY, 10065
20

21 Conflict of interest statement: We have read the journal's policy and the authors of this manuscript have
22 the following financial conflict of interest to disclose: SRP is a consultant for Moderna, Merck, Pfizer,
23 GSK, Dynavax, and Hoopika CMV vaccine programs and leads sponsored research programs with
24 Moderna, Merck, and Dynavax. She also serves on the board of the National CMV Foundation and as
25 an educator on CMV for Medscape, KMW has a sponsored research project from Moderna on immune
26 correlates of congenital CMV infection. The other authors have declared that no other conflict of interest.
27

28 **ABSTRACT**

29 Human cytomegalovirus (HCMV) is the most common vertically transmitted infection worldwide, yet
30 there are no licensed vaccines or therapeutics to prevent congenital HCMV (cCMV) infection. Emerging
31 evidence from studies of natural infection and HCMV vaccine trials indicates that antibody Fc effector
32 functions may defend against HCMV infection. We previously reported that antibody-dependent cellular
33 phagocytosis (ADCP) and IgG activation of FcγRI/FcγRII were associated with reduced risk of cCMV
34 transmission, leading us to hypothesize that other Fc-mediated antibody functions may also contribute
35 to protection. In this same cohort of HCMV transmitting (n = 41) and non-transmitting (n = 40) mother-
36 infant dyads, we found that higher maternal sera antibody-dependent cellular cytotoxicity (ADCC)
37 activation was also associated with decreased risk of cCMV infection. We determined that NK cell-
38 mediated ADCC responses correlated strongly with anti-HCMV IgG FcγRIII/CD16 activation and IgG
39 binding to the HCMV immunoevasin protein UL16. Notably, anti-UL16 IgG binding and engagement of
40 FcγRIII/CD16 were higher in non-transmitting versus transmitting dyads and interacted significantly with
41 ADCC responses. These findings indicate that ADCC-activating antibodies against novel targets such
42 as UL16 may represent an important protective maternal immune response against cCMV infection,
43 which can guide future HCMV correlates studies and vaccine development.

44

45

46

47

48

49

50

51

52

53

54

55 INTRODUCTION

56 Human cytomegalovirus (HCMV) is the most common vertically transmitted infection worldwide and has
57 been associated with stillbirth, neurodevelopmental impairment, sensorineural hearing loss, and
58 childhood leukemia (1, 2). Over 80% of reproductive age women worldwide are HCMV seropositive and
59 congenital transmission can occur following primary or non-primary HCMV infection, which may include
60 reinfection with a new strain or reactivation from viral latency (3). Despite these disease risks and the
61 ubiquity of congenital HCMV (cCMV) infection, we lack effective therapeutics and vaccines to prevent
62 HCMV transmission. Neutralizing antibodies against HCMV envelope glycoproteins (e.g., gB and
63 pentamer complex) and T cell responses have been the main targets in vaccine development to-date,
64 but these vaccines have achieved only limited to moderate efficacy (4). Moreover, several studies have
65 found that maternal neutralizing antibody titers do not correlate with reduced risk of cCMV infection (5,
66 6). We also recently reported that neutralizing antibody titers against multiple HCMV strains and cell
67 types were higher magnitude in HCMV transmitting pregnancies and not associated with protection (7).
68 Maternal administration of HCMV hyperimmunoglobulin (HCMV-HIG), a polyclonal preparation of IgG
69 from HCMV seropositive donors, following primary infection during pregnancy also failed to prevent
70 congenital transmission in two randomized clinical trials (8, 9), despite suggested efficacy in
71 observational studies (10-12). Thus, an improved understanding of the maternal antibody responses
72 that protect against cCMV infection is urgently needed to guide the development of novel vaccines and
73 immunotherapeutics (13, 14).

74

75 Antibodies can mediate polyfunctional responses such as viral neutralization through the Fab region
76 that binds antigen and non-neutralizing effector functions through the constant Fc region that binds Fc
77 receptors (FcRs) on innate immune cells. Emerging evidence indicates that anti-viral IgG effector
78 functions mediated by interactions between the IgG Fc region and FcγRs are a previously
79 underappreciated component of anti-HCMV immunity (15, 16). In our recent maternal-infant dyad study
80 reporting that neutralizing antibody titers were not correlated with protection, we found that greater Fc-
81 mediated antibody responses were associated with decreased risk of HCMV transmission (7).

82 Specifically, higher maternal sera anti-HCMV IgG engagement of FcγRI/FcγRIIa and activation of
83 antibody-dependent cellular phagocytosis (ADCP) were associated with protection against cCMV
84 infection. Therefore, we posited that additional antibody Fc effector functions may be important.

85

86 Antibody-dependent cellular cytotoxicity (ADCC) is an anti-viral Fc effector function that has been
87 underexplored in cCMV infection to-date. Natural killer (NK) cells can eliminate virally-infected cells via
88 ADCC, which is mediated by FcγRIII/CD16 expressed on the NK cell surface, or through direct cytotoxic
89 killing. HCMV has evolved many mechanisms to evade antibody-dependent and -independent NK cell
90 killing by encoding “immunoevasins” that interfere with the host immune response (17, 18). Specific
91 immune evasion strategies employed by HCMV include viral FcγR decoys that sequester IgG to prevent
92 FcγRIII activation (19, 20) and viral proteins that modulate NK cell cytotoxicity (18, 21). Nevertheless,
93 NK cell-mediated ADCC can inhibit cell-to-cell spread of HCMV in multiple cell types (22, 23), even with
94 strains that express these viral immunoevasins (24). Paradoxically, some NK cell immunoevasins (e.g.,
95 viral FcγR gp34, UL16, and UL141) have even been identified as targets of ADCC-activating IgG (24).
96 Despite evidence that ADCC mediated by certain IgG specificities can overcome viral immune evasion,
97 whether ADCC or anti-immunoevasion antibodies help limit HCMV transmission in utero is unknown.

98

99 In this study, we hypothesized that greater ADCC responses and FcγRIII/CD16 engagement by
100 maternal antibodies would be correlated with decreased risk of cCMV infection. To investigate this
101 hypothesis, we quantified ADCC responses and FcγRIII activation in maternal and cord blood sera from
102 HCMV transmitting and non-transmitting pregnancies (7). We then explored whether HCMV-specific
103 IgG directed against different antigens including envelope glycoproteins, tegument proteins, and
104 immunoevasins might contribute to protective ADCC responses. Our findings support an accumulating
105 body of evidence that Fc-mediated immunity and IgG directed against non-canonical HCMV antigens
106 are important for anti-viral control and should be considered in future correlates and vaccine studies.

107

108

109 RESULTS

110

111 Overview of mother-infant cohort

112 To determine whether ADCC-mediating antibodies may protect against cCMV, we compared antibody
113 responses in maternal and cord blood sera from HCMV seropositive transmitting (n = 41) and non-
114 transmitting (n = 40) mother-infant dyads that we previously identified as donors to a large US-based
115 public cord blood bank (**Supplementary Figure 1**) (7). Cases of cCMV infection were identified based
116 on the detection of HCMV DNAemia in the cord blood plasma and dyads were matched on infant sex,
117 race, maternal age, and delivery year. Cord blood donors were screened for clinical signs of (a) neonatal
118 sepsis, (b) congenital infection (petechial rash, hepatosplenomegaly, thrombocytopenia), and (c)
119 congenital abnormalities at birth, and only term, healthy, uncomplicated births were included.

120

121 Demographic and clinical characteristics were comparable between groups (**Table 1**) (7), but HCMV
122 serologies differed between transmitting and non-transmitting dyads. Median HCMV IgG relative avidity
123 index (RAI) scores were lower in transmitting (median = 67.7%) versus non-transmitting (median =
124 74.8%) pregnancies, and 19.5% of transmitting cases were classified as low/intermediate avidity
125 (<60%), whereas only 2.5% of non-transmitting pregnancies had low/intermediate RAI scores (**Table**
126 **1**). Additionally, 26.8% of transmitting pregnancies had HCMV-specific IgM in maternal sera versus only
127 5% of non-transmitting pregnancies (**Table 1**). While it is not possible to define primary infection,
128 reinfection, or reactivation based on HCMV serologies at a single timepoint (25, 26), these data imply
129 that the timing of maternal HCMV exposure may have differed between groups.

130

131 HCMV-specific ADCC and FcγRIII/CD16 activating antibodies are higher in non-transmitting 132 versus transmitting mother-infant dyads

133 Using NK cell degranulation (i.e., % CD107a positive NK cells) against HCMV-infected fibroblasts to
134 quantify ADCC (**Supplementary Figure 2A-B, Figure 1A**), we found that antibodies in sera from non-
135 transmitting dyads mediated significantly greater ADCC compared to transmitting dyads (**Figure 1B**,

136 **Supplementary Tables 1-2).** ADCC responses in paired cord blood and maternal sera were strongly
137 correlated, yet NK cell degranulation was significantly lower in cord blood versus maternal sera (**Figure**
138 **1B**). Few dyads had placental IgG transfer ratios >1.0 or 100% (**Figure 1B**), suggesting that the transfer
139 efficiency of ADCC-activating IgG into fetal circulation was poor. In our univariate regression analysis,
140 higher ADCC activation in maternal (OR = 0.86, p = 0.016) and cord blood sera (OR = 0.79, p = 0.005)
141 were associated with reduced risk of cCMV (**Tables 2-3**). Moreover, ADCC-activating antibodies were
142 associated with a greater magnitude reduction in transmission risk compared to our previously identified
143 immune correlate of ADCP-activating antibodies (OR = 0.94, p = 0.008) (7) (**Tables 2-3**). To assess if
144 differences in maternal HCMV exposure may be confounding these results, we compared ADCC in
145 dyads stratified by RAI score or HCMV-specific IgM status and found that ADCC activation was lower
146 in dyads with low/intermediate (median = 5.1%) versus high (median = 9.5%, p = 0.001) RAI scores
147 (**Supplementary Tables 3-4**). In a sensitivity analysis excluding dyads with low/intermediate RAI
148 scores, ADCC remained significantly associated with protection against transmission in cord blood sera
149 (OR = 0.81, p = 0.017) with a trend towards significance in maternal sera (OR = 0.89, p = 0.065,
150 **Supplementary Table 5**).

151

152 Since ADCC is primarily mediated by FcγRIII/CD16 on NK cells binding to the IgG Fc region, we
153 hypothesized that HCMV-specific IgG in non-transmitting dyads may have enhanced FcγRIII
154 engagement compared to transmitting dyads. To explore this hypothesis, we quantified anti-HCMV IgG
155 activation of FcγRIII using reporter cells expressing chimeric human FcγRIII fused to a mouse CD3ζ
156 signaling domain (**Figure 1C**). Non-transmitting dyads had significantly higher HCMV-specific IgG
157 FcγRIII activation in cord blood (p = 0.008) with a trend towards significance in maternal sera (p = 0.054)
158 (**Figure 1D, Supplementary Tables 1-2**). FcγRIII activation was lower in cord blood (median = 8791
159 μg/mL) versus maternal sera (median = 9481 μg/mL, p = 0.032) in transmitting but not non-transmitting
160 dyads (**Figure 1D**), suggesting that infected infants may receive less FcγRIII-activating IgG via placental
161 transfer. HCMV-specific IgG FcγRIII activation correlated with ADCC (**Figure 1E**) but was not
162 independently associated with transmission risk in our univariate analysis (**Tables 2-3**). Nevertheless,

163 our interaction analysis demonstrated that the association between ADCC and reduced risk of cCMV
164 infection was stronger in dyads with greater FcγRIII activation (**Tables 2-3**), suggesting that better
165 FcγRIII engagement contributed to protective ADCC responses.

166

167 **HCMV-specific ADCC and FcγRIII/CD16 activation correlate with anti-UL16 and anti-UL141 IgG**

168 Having identified that ADCC-activating antibodies were associated with protection against cCMV, we
169 aimed to define which antibodies may be contributing to this response. We hypothesized that certain
170 IgG specificities against viral immunoevasins (e.g., UL16- and UL141-specific IgG) may activate greater
171 ADCC responses in non-transmitting dyads (24). We also explored IgG responses against HCMV
172 envelope glycoproteins (e.g., gB, gH/gL, gH/gL/gO, pentamer complex) and tegument proteins (e.g.,
173 pp52, pp28, pp150) since whether they activate ADCC has been poorly characterized.

174

175 We quantified IgG binding levels against 9 HCMV antigens and measured how well these antibodies
176 bound FcγRIII. Since FcγRIII binding is influenced by IgG Fc region characteristics as well as FcγRIII
177 genetic polymorphisms, we included binding to both the high-affinity (V158) and low-affinity (F158)
178 FcγRIII variants. Hierarchical clustering identified 3 distinct clusters of antibody responses (**Figure 2**).
179 HCMV-specific ADCC (i.e., % CD107a positive NK cells), FcγRIII activation, anti-UL16, and anti-UL141
180 IgG responses correlated together in cluster 1, whereas cluster 2 consisted of IgG targeting HCMV
181 envelope glycoproteins, and cluster 3 comprised IgG responses against HCMV tegument proteins. Of
182 the 9 antigen specificities tested, only total anti-UL16 IgG binding levels were significantly correlated
183 with ADCC ($\rho = 0.42$ $p < 0.0001$; **Figure 2**), and anti-UL16 IgG binding to FcγRIII V158/F158
184 correlated most strongly with ADCC and FcγRIII activation (**Figure 2**). Anti-UL141 IgG binding to FcγRIII
185 V158/F158 were more modestly correlated with ADCC and FcγRIII activation (**Figure 2**). Despite
186 clustering separately, some anti-gB, anti-gH/gL, anti-pp28, and anti-pp150 IgG FcγRIII binding
187 responses were also modestly correlated with ADCC and/or FcγRIII activation (**Figure 2**). These
188 weaker correlations suggest that IgG against some HCMV envelope glycoproteins or tegument proteins
189 may help mediate ADCC, but likely to a lesser degree than UL16- and UL141-specific IgG.

190 **Magnitude and quality of anti-HCMV IgG binding to FcγRIII differs in non-transmitting and**
191 **transmitting dyads**

192 We previously reported that anti-HCMV IgG engagement of FcγRI/FcγRIIIa was enhanced in non-
193 transmitting dyads despite having lower magnitude anti-HCMV IgG levels (7). In this follow-up study,
194 we observed a similar phenomenon with FcγRIII engagement. Magnitude of FcγRIII binding across IgG
195 specificities against envelope or tegument proteins was higher in transmitting versus non-transmitting
196 dyads (**Figure 3A-B**); however, magnitude of antigen-specific IgG binding to FcγRIII incorporates both
197 the strength of Fab binding to the antigen and the Fc-FcγRIII interaction. Since antigen-specific IgG
198 levels differed between groups (**Supplementary Tables 1-2**), we normalized FcγRIII binding to total
199 antigen-specific IgG levels to directly compare the quality of the Fc-FcγRIII interaction. After
200 normalization, we found that the Fc region of anti-tegument IgG from non-transmitting dyads had better
201 binding to both high- and low-affinity FcγRIII (**Figure 4A-B**).

202

203 **Anti-UL16, but not anti-UL141, IgG responses are associated with reduced risk of cCMV infection**

204 Finally, we compared anti-UL141 and anti-UL16 IgG in our transmitting and non-transmitting dyads.
205 Although modestly correlated with ADCC, anti-UL141 IgG levels were slightly higher in transmitting
206 versus non-transmitting pregnancies (**Figure 5A, Supplementary Tables 1-2**), even though UL141-
207 specific IgG transfer was lower in transmitting dyads (**Supplementary Figure 3A**). While the magnitude
208 of anti-UL141 IgG binding to FcγRIII did not differ between groups, normalized anti-UL141 IgG binding
209 to FcγRIII V158/F158 was significantly higher in non-transmitters (**Figure 5B**), suggesting better quality
210 Fc-FcγRIII engagement. Nevertheless, anti-UL141 IgG binding was not associated with protection
211 against transmission in our univariate regression analysis (**Tables 2-3**). In contrast, anti-UL16 IgG levels
212 were 3-fold higher in maternal (99.8 vs. 32.3 MFI, $p = 0.019$) and 6-fold higher in cord blood (125.4 vs.
213 19.0 MFI, $p = 0.002$) sera from non-transmitting compared to transmitting pregnancies (**Figure 5C,**
214 **Supplementary Tables 1-2**). Anti-UL16 IgG levels were lower in cord blood versus maternal sera within
215 transmitting dyads, whereas anti-UL16 IgG levels were higher in cord blood versus maternal sera within
216 non-transmitting dyads (**Supplementary Figure 3B**), indicating increased UL16-specific IgG transfer

217 to uninfected infants. Anti-UL16 IgG in maternal sera of non-transmitting dyads also had 30 to 100-fold
218 higher magnitude binding to FcγRIII V158 (420.6 vs. 13.5 MFI, $p < 0.0001$) and F158 (119.4 vs. 1.0
219 MFI, $p < 0.0001$) and better quality Fc-FcγRIII binding after normalization for anti-UL16 IgG levels
220 (**Figure 5D**). Anti-UL16 IgG in maternal sera from non-transmitters also had increased functional
221 activation of FcγRIII ($p = 0.002$; **Figure 5E**) when measured with our reporter cells. In our univariate
222 regression analysis, anti-UL16 IgG binding to and activation of FcγRIII were significantly associated
223 with reduced risk of cCMV transmission (**Tables 2-3**). When comparing anti-UL16 IgG responses in
224 dyads stratified by RAI score and HCMV-specific IgM status, anti-UL16 IgG binding was significantly
225 lower in dyads with low/intermediate RAI scores or detectable HCMV-specific IgM (**Supplementary**
226 **Tables 3-4**). Nevertheless, anti-UL16 IgG binding to and activation of FcγRIII remained associated with
227 protection in a sensitivity analysis excluding these dyads (**Supplementary Tables 5-6**).

228

229 Finally, we explored if anti-UL16 IgG may contribute to greater ADCC activation using statistical
230 modeling. Our interaction analysis demonstrated that the association between maternal sera ADCC
231 activation and reduced risk of cCMV infection was stronger in dyads with higher UL16-specific IgG
232 responses (**Table 2**), indicating that anti-UL16 antibodies enhance ADCC activation in non-transmitting
233 pregnancies. These results are underscored by visualizing the correlations between anti-UL16 IgG and
234 ADCC activation stratified by cCMV status (**Figure 6A-B**), which highlight the strong positive
235 relationship between these variables ($p < 0.001$). Taken together, our data supports a model wherein
236 anti-UL16 IgG binding to FcγRIII on NK cells may mediate protective ADCC responses against HCMV
237 transmission in utero (**Figure 6C**), a hypothetical mechanism of protection that should be tested in future
238 prospective clinical cohorts and experimental studies.

239

240 **DISCUSSION**

241 Our finding that ADCC-activating antibodies are associated with protection against cCMV infection
242 contributes to a mounting body of evidence that Fc effector functions are important for host defense
243 against HCMV. During co-evolution with the human immune system, HCMV has developed numerous

244 strategies to evade Fc-mediated immunity including ADCC (18). HCMV encodes multiple viral FcγR
245 decoys that bind to host IgG to prevent FcγR engagement (19, 20, 23) and employs at least 12 viral
246 proteins to subvert NK cell killing by engaging inhibitory receptors, removing ligands for activating
247 receptors, and interfering with immunological synapse formation (17, 18, 21, 27, 28). Though Vlahava
248 et al. recently demonstrated that monoclonal antibodies and pooled polyclonal sera targeting the NK
249 cell immunoevasins UL141 and UL16 can activate ADCC (24), our study is the first to demonstrate that
250 IgG binding against these targets correlates with FcγRIII activation and NK cell degranulation in a large
251 mother-infant clinical cohort (n = 162 sera samples). Interestingly, anti-UL16, but not anti-UL141 IgG
252 responses, were associated with reduced risk of cCMV infection in our cohort. Moreover, both the
253 quantity and quality, assessed by FcγRIII engagement, of anti-UL16 IgG was greater in non-transmitting
254 dyads. UL16 blocks ligand interactions with the host NK cell activating receptor NKG2D and is highly
255 conserved across clinical HCMV strains (29-31). Thus, targeting UL16 to overcome NK cell immune
256 evasion strategies and activate maternal ADCC may be a promising strategy to prevent HCMV
257 transmission. That ADCC and anti-UL16 IgG responses were lower in dyads with low/intermediate
258 avidity scores suggests that these responses may take significant time to develop after infection and
259 could be primed by HCMV vaccination prior to pregnancy.

260

261 Our study has broad implications for HCMV vaccinology and immunotherapeutic development beyond
262 congenital infection. Neutralizing antibodies against envelope glycoproteins have been a main focus of
263 HCMV vaccines and antibody-based therapeutics (4, 32), yet there is an increasing appreciation that
264 non-neutralizing functions i.e., antibody-mediated activation of cellular immunity are a key host defense
265 strategy against HCMV. Several studies have demonstrated that protection from the gB/MF59 subunit
266 vaccine, which achieved 50% efficacy in clinical trials, was mediated by non-neutralizing antibody
267 functions, likely against the cell surface conformation of gB (15, 16, 33, 34). Antibodies elicited by the
268 gB/MF59 vaccine stimulated robust monocyte phagocytosis but not NK cell degranulation (15, 16),
269 suggesting that these vaccine-induced antibodies activate ADCP but not ADCC. Anti-gB antibodies
270 likely mediate polyfunctional responses including both phagocytosis and neutralization, a phenomenon

271 that has been observed in HIV infection (35-37); however, anti-gB IgG responses were not associated
272 with protection in our cohort. Instead, antibodies against tegument or non-structural proteins were more
273 clearly associated with reduced transmission risk and seemed poised to better activate FcγRs (24, 38).
274 In particular, our study suggests that immunoevasins (e.g., UL16) should be targeted to engage both
275 low- and high-affinity FcγRs. Taken together, our findings that antibodies stimulating ADCC and ADCP
276 correlate with protection against cCMV infection reinforces that Fc antibody effector functions should
277 be explored as immunologic targets against HCMV (7).

278

279 Further studies are needed to understand why certain antibodies against HCMV may engage FcγRs
280 and activate downstream Fc effector functions better than others. Fc-mediated antibody responses are
281 influenced by IgG Fc region characteristics such as IgG subclass and glycosylation that modify FcγR
282 binding affinity (39-44). Our finding that the Fc region of HCMV-specific IgG in non-transmitting dyads
283 had better quality FcγRIII binding and activation suggests that there may be differences in the Fc profiles
284 of transmitting versus non-transmitting pregnancies. Fc region modifications to improve anti-UL16 and
285 anti-UL141 IgG binding to FcγRIII can enhance ADCC and NK cell killing of HCMV-infected cells in vitro
286 (24). Thus, Fc-engineering could be employed in the future to improve upon antibody-based
287 therapeutics against HCMV (39). Modulating IgG Fc region characteristics to augment Fc engagement
288 could improve passive immunization strategies, which are urgently needed given the lack of efficacy of
289 HCMV hyperimmunoglobulin (HCMV-HIG) in randomized clinical trials (8, 9). It is interesting to
290 speculate whether ineffective engagement of Fc-mediated immunity may have partially contributed to
291 the failure of HCMV-HIG to prevent fetal transmission in prior clinical trials. We previously observed that
292 FcγRI-mediated ADCP of HCMV was greatly reduced in the setting of high HCMV-HIG concentrations
293 (7), leading us to hypothesize that certain Fc effector functions may have been poorly elicited in
294 pregnant people treated with HCMV-HIG, hindering its efficacy. Overall, our work highlights that Fc
295 characteristics should be considered when designing next generation polyclonal or monoclonal
296 antibodies against HCMV. Novel vaccine strategies to elicit specific IgG subclasses or glycosylation
297 profiles endogenously to enhance Fc-mediated immunity should also be explored.

298

299 The development of antibody-based prophylaxis and/or vaccines to prevent cCMV infection has been
300 hindered by our incomplete understanding of protective maternal immunity. Moreover, whether
301 antibodies mediate protection solely by limiting systemic maternal viral replication and placental
302 infection or also play a role in the fetal circulation remains unclear. We found that HCMV-specific ADCC-
303 activating antibodies were poorly transferred from maternal to cord blood sera in our cohort regardless
304 of transmission status. In contrast, ADCC-mediating antibodies against influenza and pertussis have
305 been shown to be robustly transferred across the placenta in healthy pregnancies (43). Since Fc region
306 characteristics also govern transplacental IgG transport, Fc profiles likely underlie these differences in
307 placental IgG transfer (41, 43, 44). Nevertheless, cord blood sera ADCC responses were strongly
308 associated with protection against transmission and anti-UL16 IgG was highly transferred to uninfected
309 infants. Vaaben et al. also recently observed that cord blood NK cells expressing FcγRIII/CD16 are
310 expanded in utero following cCMV infection (45, 46). Taken together, these studies suggest that
311 maternal ADCC-activating antibodies transferred across the placenta and fetal NK cells expressing
312 FcγRIII may synergize to defend against HCMV (45, 46). Therefore, strategies to enhance placental
313 transfer of these potentially protective antibodies through Fc-engineering and to engage fetal and/or
314 neonatal innate immune cells in Fc-mediated immunity should be explored.

315

316 Our study is limited by its retrospective design and relatively small sample size that reduced statistical
317 power. Due to the cross-sectional nature of this cord blood bank donor cohort, we could not identify the
318 timing of maternal HCMV acquisition or transmission during pregnancy; thus, caution is warranted in
319 interpreting our results since differences may be biased by a higher rate of primary infection, reinfection,
320 and/or reactivation in transmitting versus non-transmitting dyads. This limitation and our sensitivity
321 analyses excluding dyads with low/intermediate avidity scores or HCMV-specific IgM highlights the
322 need for future longitudinal prospective studies to investigate protective immunity against cCMV in
323 maternal primary and non-primary infection. Since all infants in the study were born healthy, we could
324 not assess clinical correlations between antibody responses and symptomatic versus asymptomatic

325 cCMV infection, which may introduce some skewing in our results. Longitudinal clinical data such as
326 neurodevelopmental outcomes and hearing loss were not collected retrospectively, so it is unknown if
327 any of the cCMV cases had delayed sequelae. Sera sample volumes were very limited, preventing
328 additional mechanistic experiments and more work is needed to define the anti-viral functions of
329 ADCC/FcγRIII activation and anti-UL16 antibodies in controlling viral replication. Maternal PBMCs were
330 not collected, so we were also unable to assess cellular correlates of protection. Whether maternal NK
331 cell abundance, phenotype, or function differs in transmitting and non-transmitting pregnancies should
332 be investigated.

333

334 In conclusion, our study indicates that ADCC and FcγRIII activating antibodies against HCMV and IgG
335 against the NK cell immunoevasion protein UL16 may help protect against cCMV infection. Our work
336 suggests that designing HCMV vaccines or antibody-based therapeutics that can engage FcγRs and
337 overcome NK cell immune evasion strategies may be an effective approach to combating this ubiquitous
338 herpesvirus that is the leading infectious cause of congenital disease and disability worldwide.

339

340 **METHODS**

341 *Study population.* We analyzed maternal (n = 81) and cord blood (n = 81) sera samples from a
342 retrospective cohort of mother-infant donors to the Carolinas Cord Blood Bank (CCBB), which has been
343 previously described in our recent complementary study (**Supplementary Figure 1**) (7). All mothers in
344 our study were HCMV IgG seropositive and cases of cCMV infection were identified by HCMV
345 DNAemia, detected by PCR, in the cord blood plasma at birth. “HCMV transmitting” cases with cCMV
346 infection (n=41) were matched to a target of 1 “HCMV non-transmitting” mother-infant dyad (n=40).
347 Maternal HCMV IgG seropositivity was confirmed by a whole-virion HCMV ELISA and HCMV IgM
348 seropositivity was determined using a clinical diagnostic ELISA (Bio-Rad CMV IgM EIA Kit). HCMV-
349 specific IgG relative avidity index (RAI) scores were determined by calculating the mean RAI across 3
350 HCMV strains (TB40/E, AD169r, and Toledo virus) using whole virion ELISA using urea as the
351 dissociation agent as previously described (7). Maternal RAI scores < 60% were defined as

352 low/intermediate avidity and \geq to 60% were defined as high avidity (25). Matching criteria included
353 infant sex, infant race, maternal age, and delivery year. Only people with healthy, uncomplicated
354 pregnancies that gave birth at term were included in our study; cord blood donors were screened for
355 signs of (a) neonatal sepsis, (b) congenital infection (petechial rash, thrombocytopenia,
356 hepatosplenomegaly), and (c) congenital abnormalities.

357

358 *Natural killer (NK) cell-mediated ADCC.* NK cell degranulation was quantified by cell-surface expression
359 of CD107a as previously described (47). MRC-5 fibroblasts (target cells; ATCC) were infected with
360 HCMV strain AD169r (a AD169 derivative with repaired UL128-131 expression named BadrUL131-Y4-
361 GFP (48)) at an MOI of 1.0 or mock-infected. After 48 hours, primary human NK cells (effector cells)
362 were isolated by negative selection with magnetic beads (human NK cell isolation kit, Miltenyi Biotech)
363 from PBMCs of a healthy adult donor then live, primary NK cells were added to each well containing
364 HCMV-infected or mock-infected fibroblasts at an E:T ratio of 1:1. Cytogam IgG product or diluted sera
365 samples (1:75) were then added with brefeldin A (GolgiPlug; BD Biosciences), monensin (GolgiStop;
366 BD Biosciences), and anti-CD107a-FITC (clone H4A3; BD Biosciences). After a 6-hour incubation, NK
367 cells were stained with anti-CD56-PE/Cy7 (clone NCAM16.2; BD Biosciences), anti-CD16-PacBlue
368 (clone 3G8; BD Biosciences), and a viability dye (Live/Dead Aqua Dead Cell Stain, ThermoFisher).
369 Events were acquired on an LSR Fortessa flow cytometer, and the frequencies of live, CD107a positive
370 NK cells were calculated in FlowJo (gating strategy in **Supplementary Figure 2**). To correct for non-
371 specific degranulation activity, the signal in mock-infected wells was subtracted from the signal in
372 HCMV-infected wells for each sera sample (**Supplementary Figure 2**).

373

374 *HCMV antigen-specific IgG binding.* IgG binding to HCMV antigens including UL16 and UL141
375 (provided by R. Stanton), envelope glycoproteins (gB ectodomain, pentamer complex, gH/gL/gO,
376 gH/gL), and tegument proteins (pp28, pp150, pp52) was quantified using a binding antibody multiplex
377 assay (BAMA) as previously described (7). In brief, HCMV antigens were coupled to intrinsically
378 fluorescent beads (Bio-Plex pro magnetic COOH beads, Bio-Rad) then co-incubated with serially diluted

379 Cytogam IgG product (CSL Behring) or sera samples. Antigen-specific IgG binding was detected with
380 mouse anti-human IgG-PE (Southern Biotech) and MFI was acquired on a Bio-Plex 200.

381

382 *HCMV antigen-specific IgG binding to FcγRs.* Antigen-specific IgG binding to FcγRIII/CD16 was
383 measured using a modified BAMA as previously described (7). Purified human FcγRIII high-affinity
384 (V158) and low-affinity (F158) variants were produced by the DHVI Protein Production Facility and
385 biotinylated in-house. First, sera samples were co-incubated with HCMV antigen-coated beads, as
386 above. Next, biotinylated FcγRIII was complexed with streptavidin-PE (BD Biosciences) then co-
387 incubated with antibody-bound beads and MFI was acquired on a Bio-Plex 200.

388

389 *FcγR IgG activation.* HCMV-specific IgG activation of FcγRIII/CD16 was quantified using mouse BW
390 thymoma cells expressing chimeric FcγR-CD3ζ as previously described (7, 49). To confirm FcγR
391 expression, BW cells were stained with anti-FcγRI/CD64-PE (clone 10.1, eBioscience), anti-
392 FcγRII/CD32-PE (clone 6C4, eBioscience), anti-FcγRIII/CD16-PE (clone CB16, eBioscience), and anti-
393 Ig-PE isotype control (eBioscience). Events were acquired on a LSRII flow cytometer then analyzed
394 using FlowJo. To quantify FcγR activation, 96-well plates were coated with HCMV strain AD169r
395 (20,000 PFU/well) or UL16 antigen (250 μg/well) then co-incubated with Cytogam IgG product or sera
396 samples (diluted 1:10) to form immune complexes. Next, FcγRIII-expressing BW cells were added and
397 incubated for 20 hours. Cell supernatants were then harvested, and mouse IL-2 levels were quantified
398 as a read-out of FcγRIII-CD3ζ activation using ELISA as previously described (7).

399

400 *Statistics.* All primary data underwent independent quality control by another lab member using
401 standardized criteria base on duplicate well variance and performance of positive and negative controls,
402 which included Cytogam, HCMV seropositive, and HCMV seronegative sera samples. Wilcoxon rank-
403 sum tests were used to compare transmitting and non-transmitting dyads and Wilcoxon signed rank
404 tests were used to assess differences within dyads. Spearman's correlation coefficient was calculated
405 for select immune variables and correlation matrices were plotted using the corrplot package in R v4.1.

406 ELISA and BAMA data were log-transformed for all regression analyses. Statistical significance was
407 defined a priori as $p < 0.05$ after an FDR correction for multiple comparisons. Statistical analyses were
408 completed in R v4.1 and GraphPad Prism v9.1.

409

410 *Study Approval.* Approval was obtained from Duke University School of Medicine's Institutional Review
411 Board (Pro00089256) to use deidentified clinical data and biospecimens provided by the CCBB. No
412 patients were prospectively recruited for this study, and all samples were acquired retrospectively from
413 the CCBB biorepository from donors who had previously provided written consent for banked
414 biospecimens to be used for research.

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433 **Author contributions**

434 ECS, JP, and SRP designed the research study. ECS, IGM, NR, and CP conducted the experiments
435 and acquired the data. ECS, IGM, and NR completed the primary data analysis. ECS completed the
436 statistical analyses with oversight from KMW. SRP and KMW acquired funding for the study. JHH
437 helped acquire the human samples and RS provided key reagents for the study. ECS wrote the primary
438 draft of the manuscript. ECS, IGM, NR, CP, JHH, KMW, JP, RS and SRP all contributed to writing and
439 editing the manuscript.

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460 **Acknowledgements**

461 Thank you to the CCBB donors, CCBB director Dr. Joanne Kurtzberg, and CCBB staff including Jose
462 Hernandez, Ann Kaestner, and Korrynn Vincent who were instrumental in acquiring the biospecimens
463 and donor clinical information for this study. We also would like to thank Drs. Phillip Kolb and Hartmut
464 Hengel who generously provided the FcR-transfected BW cell lines. This project was supported by NIH
465 NCI 1R21CA242439-01 “Immune Correlates and Mechanisms of Perinatal Cytomegalovirus Infection
466 and Later Life ALL Development” to KMW and SRP and NIH NIAID 1R21-AI147992 “Humoral immune
467 correlates of protection against congenital CMV and HSV transmission in HIV-infected women” to SRP.
468 This project was also partially sponsored by Moderna. The funders had no role in study design, data
469 collection and analysis, decision to publish, or preparation of the manuscript.

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487 References

- 488 1. Boppana SB, Ross SA, and Fowler KB. Congenital cytomegalovirus infection: clinical outcome.
489 *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.*
490 2013;57 Suppl 4:S178-81.
- 491 2. Francis SS, Wallace AD, Wendt GA, Li L, Liu F, Riley LW, et al. In utero cytomegalovirus
492 infection and development of childhood acute lymphoblastic leukemia. *Blood.*
493 2017;129(12):1680-4.
- 494 3. Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleeschauwer B, et al. Estimation of the
495 worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. *Reviews*
496 *in medical virology.* 2019;29(3):e2034.
- 497 4. Gerna G, and Lilleri D. Human cytomegalovirus (HCMV) infection/re-infection: development of
498 a protective HCMV vaccine. *New Microbiol.* 2019;42(1):1-20.
- 499 5. Vanarsdall AL, Chin AL, Liu J, Jardetzky TS, Mudd JO, Orloff SL, et al. HCMV trimer- and
500 pentamer-specific antibodies synergize for virus neutralization but do not correlate with
501 congenital transmission. *Proceedings of the National Academy of Sciences of the United States*
502 *of America.* 2019;116(9):3728-33.
- 503 6. Dorfman JR, Balla SR, Pathirana J, Groome MJ, Madhi SA, and Moore PL. In utero human
504 cytomegalovirus infection is associated with increased levels of putatively protective maternal
505 antibodies in nonprimary infection: evidence for boosting but not protection. *Clinical infectious*
506 *diseases : an official publication of the Infectious Diseases Society of America.* 2021.
- 507 7. Semmes EC, Miller IG, Wimberly CE, Phan CT, Jenks JA, Harnois MJ, et al. Maternal Fc-
508 mediated non-neutralizing antibody responses correlate with protection against congenital
509 human cytomegalovirus infection. *The Journal of clinical investigation.* 2022.
- 510 8. Hughes BL, Clifton RG, Rouse DJ, Saade GR, Dinsmoor MJ, Reddy UM, et al. A Trial of
511 Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection. *The New England*
512 *journal of medicine.* 2021;385(5):436-44.
- 513 9. Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, et al. A randomized
514 trial of hyperimmune globulin to prevent congenital cytomegalovirus. *The New England journal*
515 *of medicine.* 2014;370(14):1316-26.
- 516 10. Nigro G, and Adler SP. Hyperimmunoglobulin for prevention of congenital cytomegalovirus
517 disease. *Clinical infectious diseases : an official publication of the Infectious Diseases Society*
518 *of America.* 2013;57 Suppl 4:S193-5.
- 519 11. Nigro G, Adler SP, Parruti G, Anceschi MM, Coclite E, Pezone I, et al. Immunoglobulin therapy
520 of fetal cytomegalovirus infection occurring in the first half of pregnancy--a case-control study of
521 the outcome in children. *The Journal of infectious diseases.* 2012;205(2):215-27.
- 522 12. Nigro G, Adler SP, La Torre R, and Best AM. Passive immunization during pregnancy for
523 congenital cytomegalovirus infection. *The New England journal of medicine.*
524 2005;353(13):1350-62.
- 525 13. Britt WJ. Congenital Human Cytomegalovirus Infection and the Enigma of Maternal Immunity.
526 *Journal of virology.* 2017;91(15).
- 527 14. Permar SR, Schleiss MR, and Plotkin SA. Advancing Our Understanding of Protective Maternal
528 Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus
529 Infections. *Journal of virology.* 2018;92(7).
- 530 15. Nelson CS, Huffman T, Jenks JA, Cisneros de la Rosa E, Xie G, Vandergrift N, et al. HCMV
531 glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
532 *Proceedings of the National Academy of Sciences of the United States of America.*
533 2018;115(24):6267-72.
- 534 16. Baraniak I, Kropff B, Ambrose L, McIntosh M, McLean GR, Pichon S, et al. Protection from
535 cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing
536 antibodies. *Proceedings of the National Academy of Sciences of the United States of America.*
537 2018;115(24):6273-8.

- 538 17. Patel M, Vlahava VM, Forbes SK, Fielding CA, Stanton RJ, and Wang ECY. HCMV-Encoded
539 NK Modulators: Lessons From in vitro and in vivo Genetic Variation. *Frontiers in immunology*.
540 2018;9:2214.
- 541 18. Berry R, Watson GM, Jonjic S, Degli-Esposti MA, and Rossjohn J. Modulation of innate and
542 adaptive immunity by cytomegaloviruses. *Nature reviews Immunology*. 2020;20(2):113-27.
- 543 19. Corrales-Aguilar E, Trilling M, Hunold K, Fiedler M, Le VT, Reinhard H, et al. Human
544 cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III. *PLoS*
545 *pathogens*. 2014;10(5):e1004131.
- 546 20. Corrales-Aguilar E, Hoffmann K, and Hengel H. CMV-encoded Fcγ receptors: modulators at the
547 interface of innate and adaptive immunity. *Seminars in immunopathology*. 2014;36(6):627-40.
- 548 21. Stanton RJ, Prod'homme V, Purbhoo MA, Moore M, Aicheler RJ, Heinzmann M, et al. HCMV
549 pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells. *Cell Host*
550 *Microbe*. 2014;16(2):201-14.
- 551 22. Wu Z, Sinzger C, Frascaroli G, Reichel J, Bayer C, Wang L, et al. Human cytomegalovirus-
552 induced NKG2C(hi) CD57(hi) natural killer cells are effectors dependent on humoral antiviral
553 immunity. *Journal of virology*. 2013;87(13):7717-25.
- 554 23. Wu Z, Sinzger C, Reichel JJ, Just M, and Mertens T. Natural killer cells can inhibit the
555 transmission of human cytomegalovirus in cell culture by using mechanisms from innate and
556 adaptive immune responses. *Journal of virology*. 2015;89(5):2906-17.
- 557 24. Vlahava VM, Murrell I, Zhuang L, Aicheler RJ, Lim E, Miners KL, et al. Monoclonal antibodies
558 targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus. *The*
559 *Journal of clinical investigation*. 2021;131(4).
- 560 25. Prince HE, and Lapé-Nixon M. Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing
561 primary CMV infection during pregnancy. *Clinical and vaccine immunology : CVI*.
562 2014;21(10):1377-84.
- 563 26. Gerna G, Fornara C, Furione M, and Lilleri D. Congenital Human Cytomegalovirus Infection: A
564 Narrative Review of Maternal Immune Response and Diagnosis in View of the Development of
565 a Vaccine and Prevention of Primary and Non-Primary Infections in Pregnancy. *Microorganisms*.
566 2021;9(8).
- 567 27. Fielding CA, Weekes MP, Nobre LV, Ruckova E, Wilkie GS, Paulo JA, et al. Control of immune
568 ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell
569 activation. *Elife*. 2017;6.
- 570 28. Wang ECY, Pjechova M, Nightingale K, Vlahava VM, Patel M, Ruckova E, et al. Suppression of
571 costimulation by human cytomegalovirus promotes evasion of cellular immune defenses.
572 *Proceedings of the National Academy of Sciences of the United States of America*.
573 2018;115(19):4998-5003.
- 574 29. Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel
575 MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity
576 through the NKG2D receptor. *Immunity*. 2001;14(2):123-33.
- 577 30. Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W, et al. ULBP1, 2, 3: novel
578 MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate
579 NK cells. *European journal of immunology*. 2001;31(5):1428-37.
- 580 31. Suárez NM, Wilkie GS, Hage E, Camiolo S, Holton M, Hughes J, et al. Human Cytomegalovirus
581 Genomes Sequenced Directly From Clinical Material: Variation, Multiple-Strain Infection,
582 Recombination, and Gene Loss. *The Journal of infectious diseases*. 2019;220(5):781-91.
- 583 32. Sardonís V, García-Ríos E, McConnell MJ, and Pérez-Romero P. Role of Neutralizing
584 Antibodies in CMV Infection: Implications for New Therapeutic Approaches. *Trends Microbiol*.
585 2020;28(11):900-12.
- 586 33. Jenks JA, Nelson CS, Roark HK, Goodwin ML, Pass RF, Bernstein DI, et al. Antibody binding
587 to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans.
588 *Science translational medicine*. 2020;12(568).

- 589 34. Bernstein DI, Munoz FM, Callahan ST, Rupp R, Wootton SH, Edwards KM, et al. Safety and
590 efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized
591 clinical trial. *Vaccine*. 2016;34(3):313-9.
- 592 35. Richardson SI, Lambson BE, Crowley AR, Bashirova A, Scheepers C, Garrett N, et al. IgG3
593 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly
594 neutralizing antibody. *PLoS pathogens*. 2019;15(12):e1008064.
- 595 36. Richardson SI, Chung AW, Natarajan H, Mabvakure B, Mkhize NN, Garrett N, et al. HIV-specific
596 Fc effector function early in infection predicts the development of broadly neutralizing antibodies.
597 *PLoS pathogens*. 2018;14(4):e1006987.
- 598 37. Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, et al. Polyfunctional Fc-
599 effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.
600 *Science translational medicine*. 2014;6(228):228ra38.
- 601 38. Elder E, Krishna B, Williamson J, Aslam Y, Farahi N, Wood A, et al. Monocytes Latently Infected
602 with Human Cytomegalovirus Evade Neutrophil Killing. *iScience*. 2019;12:13-26.
- 603 39. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants
604 with enhanced effector function. *Proceedings of the National Academy of Sciences of the United
605 States of America*. 2006;103(11):4005-10.
- 606 40. Nimmerjahn F, and Ravetch JV. Fcγ receptors as regulators of immune responses.
607 *Nature reviews Immunology*. 2008;8(1):34-47.
- 608 41. Jennewein MF, Abu-Raya B, Jiang Y, Alter G, and Marchant A. Transfer of maternal immunity
609 and programming of the newborn immune system. *Seminars in immunopathology*.
610 2017;39(6):605-13.
- 611 42. Tay MZ, Wiehe K, and Pollara J. Antibody-Dependent Cellular Phagocytosis in Antiviral Immune
612 Responses. *Frontiers in immunology*. 2019;10:332.
- 613 43. Jennewein MF, Goldfarb I, Dolatshahi S, Cosgrove C, Noelette FJ, Krykbaeva M, et al. Fc
614 Glycan-Mediated Regulation of Placental Antibody Transfer. *Cell*. 2019;178(1):202-15.e14.
- 615 44. Martinez DR, Fong Y, Li SH, Yang F, Jennewein MF, Weiner JA, et al. Fc Characteristics
616 Mediate Selective Placental Transfer of IgG in HIV-Infected Women. *Cell*. 2019;178(1):190-
617 201.e11.
- 618 45. Vaaben AV, Levan J, Nguyen CBT, Callaway PC, Prah M, Warriar L, et al. In Utero Activation
619 of NK Cells in Congenital CMV Infection. *The Journal of infectious diseases*. 2022.
- 620 46. Semmes EC, and Permar SR. Human cytomegalovirus infection primes fetal NK cells for Fc-
621 mediated anti-viral defense. *The Journal of infectious diseases*. 2022.
- 622 47. Harnois MJ, Dennis M, Stöhr D, Valencia SM, Rodgers N, Semmes EC, et al. Elite neutralizers
623 of human cytomegalovirus are characterized by high magnitude plasma IgG responses against
624 multiple glycoprotein complexes. *The Journal of infectious diseases*. 2022.
- 625 48. Wang D, and Shenk T. Human cytomegalovirus UL131 open reading frame is required for
626 epithelial cell tropism. *Journal of virology*. 2005;79(16):10330-8.
- 627 49. Corrales-Aguilar E, Trilling M, Reinhard H, Mercé-Maldonado E, Widera M, Schaal H, et al. A
628 novel assay for detecting virus-specific antibodies triggering activation of Fcγ receptors. *J
629 Immunol Methods*. 2013;387(1-2):21-35.
- 630

Table 1. Overview of case-control cord blood donor mother-infant cohort

	HCMV transmitting (n=41)	HCMV non-transmitting (n=40)
Infant sex, n (%)		
Female	17 (41.5%)	16 (40.0%)
Male	24 (58.5%)	24 (60.0%)
Infant race/ethnicity, n (%)		
White	26 (63.4%)	24 (60.0%)
Black or African American	8 (19.5%)	8 (20.0%)
Hispanic or Latino	2 (4.9%)	2 (5.0%)
Other	5 (12.2%)	6 (15.0%)
Maternal age (years), median [IQR]	27 [23, 31]	28 [24, 33]
Gestational age (months), median [IQR]	39.0 [39.0, 40.0]	39.0 [38.0, 40.0]
Delivery year, median [range]	2013 [2010, 2015]	2012 [2008, 2017]
Delivery type, n (%)		
Vaginal	18 (43.9%)	24 (60.0%)
Cesarean section	23 (56.1%)	16 (40.0%)
Maternal HCMV IgG avidity score^a, median [IQR]	67.7 [63.8-70.9]	74.8 [71.9-78.3]
Maternal HCMV IgG avidity score^a, n (%)		
Low/intermediate (< 60%)	8 (19.5%)	1 (2.5%)
High (≥ 60%)	33 (80.5%)	39 (97.5%)
Maternal HCMV IgM seropositivity, n (%)		
Seropositive	11 (26.8%)	2 (5.0%)
Seronegative	30 (73.2%)	38 (95.0%)
Maternal sera HCMV DNAemia, n (%)		
Positive	11 (26.8%)	15 (37.5%)
Negative	30 (73.2%)	25 (62.5%)
Maternal sera HCMV viral copies, median [range]^b	346 [256-1052]	365 [260-719]
Cord blood sera HCMV viral copies, median [range]^b	727 [137-18,100]	ND

ND = not detected

^a Maternal HCMV IgG relative avidity index (RAI) score was calculated as the mean HCMV-specific IgG RAI measured against 3 HCMV strains including TB40E, AD169r, and Toledo virus. RAI scores <60% were considered low/intermediate avidity whereas scores ≥60% were considered high avidity based on numerous previous publications (Prince et al.).

^b Maternal HCMV viral copies listed in viral copies/mL, lower limit of detection = 250 copies/mL

^c Cord blood HCMV viral copies detected listed in IU/mL, lower limit of detection = 137 copies/mL

Transmitting and non-transmitting dyads were matched on maternal age (+/- 3 years), infant race, sex, and delivery year (+/- 3 years)




Figure 1. HCMV-specific ADCC and FcγRIII/CD16 activating antibodies in HCMV transmitting versus non-transmitting mother-infant dyads. HCMV-specific ADCC and FcγRIII IgG activation was measured using maternal (M) and cord blood (CB) sera from HCMV transmitting (red circles, n = 41) and non-transmitting (blue diamonds, n = 40) mother-infant dyads. Antibody responses were compared between and within dyads. (A) NK cell degranulation (% CD107a positive NK cells; gating strategy in Supplementary Figure 2) was quantified as a read-out of ADCC using a flow-based assay. Primary NK cells were isolated from PBMCs by negative selection with magnetic beads prior to co-incubation with HCMV-infected and mock-infected cells. Cytogam (light green), HCMV seropositive (light and dark blue), and HCMV seronegative (grey) sera samples were included as controls. (B) HCMV-specific antibody ADCC responses in transmitting and non-transmitting dyads. (C) Flow cytometry of FcγR-CD3ζ BW cells showing unstained (red), isotype control (orange), anti-FcγRI/CD64 (light green), anti-FcγRII/CD32 (blue), and anti-FcγRIII/CD16 (purple) PE-conjugated antibody staining. (D) Anti-HCMV IgG FcγRIII activation in transmitting and non-transmitting dyads. (E) Scatterplots showing Spearman correlations between HCMV-specific ADCC and FcγRIII IgG activation. IgG transfer ratio equals paired cord blood/maternal sera responses. Horizontal black bars denote median. FDR-corrected *P* values for Mann-Whitney U test or Wilcoxon signed-rank test. * *P* < 0.05, ***P* < 0.01, ****P* < 0.001.

Table 2. Univariate logistic regression and interaction analysis of maternal sera antibody responses and risk of congenital HCMV transmission

Antibody variable	Univariate			HCMV ADCC Interaction		
	OR ^a	95% CI	p value	R ^b	95% CI	p value
HCMV ADCC	0.86	0.77 - 0.97	0.016	-	-	-
HCMV ADCP^c	0.94	0.90 - 0.98	0.008	0.99	0.98 - 1.00	0.079
HCMV IgG FcγRIII activation	0.93	0.63 - 1.37	0.700	1.30	1.08 - 1.57	0.005
UL141 IgG binding level	2.53	1.31 - 4.89	0.001	0.95	0.81 - 1.13	0.586
UL141 IgG FcγRIII V158	0.99	0.67 - 1.46	0.962	1.09	0.98 - 1.23	0.113
UL141 IgG FcγRIII F158	0.97	0.66 - 1.43	0.899	1.05	0.93 - 1.19	0.439
UL16 IgG binding level	0.79	0.60 - 1.05	0.101	1.12	1.02 - 1.23	0.023
UL16 IgG FcγRIII V158	0.70	0.58 - 0.86	0.001	1.06	0.99 - 1.12	0.071
UL16 IgG FcγRIII F158	0.75	0.63 - 0.88	0.001	1.06	1.01 - 1.12	0.025
UL16 IgG FcγRIII activation	0.82	0.70 - 0.96	0.012	1.05	1.00 - 1.10	0.037

^a OR < 1.0 is associated with decreased risk and OR > 1.0 is associated with increased risk of congenital HCMV transmission.

^b R = ratio of odds ratios for the interaction term between HCMV ADCC (measured as NK cell degranulation) and HCMV-specific antibody responses.

^c Antibody-dependent cellular phagocytosis (ADCP) was measured previously in Semmes et al. 2022.

Bold indicates statistical significance (p < 0.05)

Table 3. Univariate logistic regression and interaction analysis of cord blood sera antibody responses and risk of congenital HCMV transmission

Antibody variable	Univariate			HCMV ADCC Interaction		
	OR ^a	95% CI	p value	R ^b	95% CI	p value
HCMV ADCC	0.79	0.68 - 0.93	0.005	-	-	-
HCMV ADCP ^c	1.00	0.96 - 1.04	0.944	1.01	1.00 - 1.02	0.231
HCMV IgG FcγRIII activation	0.93	0.65 - 1.33	0.696	1.21	1.02 - 1.43	0.026
UL141 IgG binding level	1.97	1.12 - 3.47	0.018	1.05	0.89 - 1.23	0.567
UL141 IgG FcγRIII V158	1.12	0.77 - 1.64	0.558	1.21	0.99 - 1.47	0.057
UL141 IgG FcγRIII F158	1.22	0.76 - 1.99	0.406	1.08	0.90 - 1.30	0.381
UL16 IgG binding level	0.75	0.55 - 1.00	0.051	1.10	0.99 - 1.24	0.073
UL16 IgG FcγRIII V158	0.69	0.56 - 0.85	0.001	1.04	0.96 - 1.12	0.323
UL16 IgG FcγRIII F158	0.73	0.61 - 0.87	0.001	1.03	0.97 - 1.10	0.294
UL16 IgG FcγRIII activation	0.95	0.83 - 1.08	0.472	1.03	0.97 - 1.08	0.319

^a OR < 1.0 is associated with decreased risk and OR > 1.0 is associated with increased risk of congenital HCMV transmission.

^b R = ratio of odds ratios for the interaction term between HCMV ADCC (measured as NK cell degranulation) and HCMV-specific antibody responses.

^c Antibody-dependent cellular phagocytosis (ADCP) was measured previously in Semmes et al. 2022.

Bold indicates statistical significance (p < 0.05)




Figure 2. HCMV-specific NK cell ADCC and FcγRIII/CD16 activating antibodies cluster with anti-UL16 and anti-UL141 IgG responses. Hierarchical clustering was performed on Spearman correlation coefficients to group strongly correlated immune variables. Matrix of maternal sera antibody responses showing Spearman correlation coefficients from -1.0 (blue) to +1.0 (red). Non-significant correlations ($P > 0.05$) shown in white. MFI = mean florescent intensity. Level = total antigen-specific IgG binding measured by a binding antibody multiplex assay. gB-transfected cell IgG = IgG binding to cell-associated gB as measured in Semmes et al. 2022.




Figure 3. HCMV antigen-specific IgG binding magnitude to FcγRIII/CD16 in transmitting versus non-transmitting dyads. HCMV antigen-specific IgG binding to FcγRIII in maternal (M) and cord blood (CB) sera was measured using a binding antibody multiplex assay with a biotinylated FcγR and streptavidin-PE detection antibody. HCMV antigen-specific IgG binding to FcγRIII was compared between transmitting (red circles, n = 41) and non-transmitting (blue diamonds, n = 40) mother-infant dyads. (A) HCMV antigen-specific IgG binding to FcγRIII high-affinity V158 variant. (B) HCMV antigen-specific IgG binding to FcγRIII low-affinity F158 variant. Horizontal black bars denote median. FDR-corrected *P* values reported for Mann-Whitney U test. * *P* < 0.05, ** *P* < 0.01, *** *P* < 0.001.




Figure 4. HCMV antigen-specific IgG binding quality to FcγRIII/CD16 in transmitting versus non-transmitting dyads. HCMV antigen-specific IgG binding to FcγRIII in maternal (M) and cord blood (CB) sera was measured using a binding antibody multiplex assay with a biotinylated FcγR and streptavidin-PE detection antibody. Antigen-specific IgG binding to FcγRIII was normalized to total antigen-specific IgG binding (i.e., total antigen-specific IgG level) as a ratio and compared between transmitting (red circles, n = 41) and non-transmitting (blue diamonds, n = 40) mother-infant dyads. (A) Normalized HCMV antigen-specific IgG binding to FcγRIII high-affinity V158 variant. (B) Normalized HCMV antigen-specific IgG binding to FcγRIII low-affinity F158 variant. Horizontal black bars denote median. FDR-corrected *P* values reported for Mann-Whitney U test. * *P* < 0.05, ***P* < 0.01, ****P* < 0.001.




Figure 5. Anti-UL141 and anti-UL16 Ig binding in HCMV transmitting versus non-transmitting mother-infant dyads. Anti-UL141 and anti-UL16 IgG binding was measured with a binding antibody multiplex assay using maternal (M) and cord blood (CB) sera from HCMV transmitting (red circles, n = 41) and non-transmitting (blue diamonds, n = 40) mother-infant dyads. (A) Total anti-UL141 IgG binding (i.e., level). (B) Anti-UL141 IgG binding to FcγRIII high-affinity V158 and low-affinity F158 variants before and after normalization for total anti-UL141 IgG level. (C) Total anti-UL16 IgG binding (i.e., level). (D) Anti-UL16 IgG binding to FcγRIII high-affinity V158 and low-affinity F158 variants before and after normalization for total anti-UL16 IgG level. (E) Anti-UL16 IgG FcγRIII activation measured via FcγR-CD3ζ BW cell activation assay. FDR-corrected *P* values reported for Mann-Whitney U test. * *P* < 0.05, ** *P* < 0.01, *** *P* < 0.001.




Figure 6. Anti-UL16 IgG binding and ADCC-activating antibodies are correlated and boosted in HCMV non-transmitting dyads. HCMV-specific ADCC (i.e., NK cell degranulation) and anti-UL16 IgG binding were measured using maternal sera from HCMV transmitting (red circles, n = 41) and non-transmitting (blue diamonds, n = 40) mother-infant dyads. (A) Scatterplots showing Spearman correlation between anti-UL16 IgG binding and ADCC. (B) Scatterplots showing Spearman correlation between ADCC and anti-UL16 IgG binding to FcγRIII high-affinity V158 and low-affinity F158 variants. (C) Hypothetical model demonstrating proposed role for anti-UL16 IgG binding and FcγRIII in mediating NK cell ADCC against HCMV-infected cells.